Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

Inclusion Criteria:

• Provide signed informed consent

• Adults of any gender, race, or ethnicity and aged 45 to 76 years at time ofenrollment

• Cognitive impairment or early-stage dementia as demonstrated by combination of AQ-21score >4 and either:

• MoCA 18-26, inclusive, or

• greater than or equal 2 scores in the bottom 50th percentilve for NCI or ExecutiveFunction, Verbal, Visual, or Composite sub-tests

• Proficient in spoken and written English for informed consent and study procedures

• Have a willing and able study partner to support participant with compliance and allaspects of teh protocol and provide input for subjective ratings of theparticipant's cognitive status. The study partner must interact with teh participantfrequently (live with or have daily contact with participant), and have sufficientlyclose relationship to observe and understand participant's difficulties with memorand activities of daily living.

• All exisiting medical conditions and any current medication dosages must be stable

• Have regular access to computer and internet connection and an iOS or AndroidSmartphone or tablet capable of connecting to devices and applications used in thestudy

• Ability to use a computer and web interface, or have readily available assistance tofacilitate the use of a computer and web interface

• Ability to converse with a coach or provider virtually to access the virtualcoaching aspects of the treatment approach

• Willing and able to follow the protocol procesured and testing, including changes indiet, lifestyle, supplements, and medications

• Willing to have at least one home visit by the study health coach, including homeevaluation for toxins or mold

• Willingness to remediate and/or move away from identifies sources of toxicity suchas molds or other toxins or infections or dental decay

• Willingness to comply with COVID prevention precautions

• Participants taking Aricept will be considered if they have been using Aricept forat least 90 days prior to study adminission. Must be on a stable dose for at least 90-days prior to screening and agree to remian on the same dose throughout thecourse of the study.

• Women who are premenopausal and sexually active must be willing to use appropriatecontraception and have repeated pregnancy tests as indicated

• Willing to have an MRI and coronary artery calcium scan

• Live within 1-1.5 hours of the study site

• Women only: willing to complete the health screening exams and remediate any healthissues detected during these screening exams: 1) Mammogram within 12 months ofrandomization; 2) Pelvic exam within 12 moths for women less than 60 years or pelvicexam within 24 months if 60 years or older.

Exclusion Criteria:

• Presence of any uncontrolled major medical illness, seizures, or cardiovasculardisease

• Diagnosis of Type 1 Diabetes

• Presence of any major psychiatric diagnoses that impact the performance ofactivities of daily living or functioning, other than those related to cognitivedecline

• Use of psychoactive medications known to impact cognition, unless willing andeligible to discontinue

• Use of chronic anticoagulation therapy, other than prophylactic aspirin orproteolytic enzymes, or a history of recurrent deep vein thrombosis

• MRI findings of hydrocephalus, focal stroke, extinsive white matter disease or braintumor

• Prior traumatic brain injury of sufficient severity to impact functioning on aregular basis

• Diagnosis of cancer in past 5 years, or any history or breast cancer; exclusive ofmelanoma skin cancers or ductal carcinoma in situ.

• Positive test for HIV, Hepatitis C, or RPR (rapid plasma reagin)

• Menopausal and perimenopausal women who are unwilling or unable to use bioidenticalhormone replacement therapy

• Positive preganance test

• Presence of an existing daignosis of non-Alzheimer's neurodegenerative disorderssuch as Lewy Body Disease, Frontotemporal Disease, Chronic Traumatic Encephalopathy,Korsakoff's Syndrome, etc.

• A diagnosis of cerebrovascular disease as the primary cause of cognitive impairmentor early-stage dementia

• Lack of adequate support from a study partner to assist with study adherence

• Inability to exercise

• Inabilty to use a computer with or without assistance; or no computer access

• Plans to travel or be away from home for more than 2 weeks during the course of the 9-month study

• Previous treatment using dietary changes, comprehensive nutritional support, ReCODEProgram, or similar methodology such as functional, integrative, or systems medicineat a level considered by the investigator to interfere with the study goals

• Any contraindication to enclosed MRI

• Unwilling or unable to comply with general study procedures

• Current user of tobacco

• Unwilling or unable to remediate or move away from identified sources of toxicities (molds, toxins, infections, dental decay)

• Use of Aricept off-label

• Two or more CNS-Vital Sign tests are invalid at baseline